Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation.

Heike Hofmann-Winkler,Onnen Moerer,Sabine Alt-Epping,Anselm Bräuer,Benedikt Büttner,Martin Müller,Torben Fricke,Julian Grundmann,Lars-Olav Harnisch,Daniel Heise,Andrea Kernchen,Meike Pressler,Caspar Stephani,Björn Tampe,Artur Kaul,Sabine Gärtner,Stefanie Kramer,Stefan Pöhlmann,Martin Sebastian Winkler

Critical care explorations（2020）

引用 40|浏览17

暂无评分

摘要

The severity of coronavirus disease 2019 decreased upon camostat mesylate treatment within a period of 8 days and a similar effect was not observed in patients receiving hydroxychloroquine. Camostat mesylate thus warrants further evaluation within randomized clinical trials.

查看译文

关键词

Sepsis-related Organ Failure Assessment,camostat mesylate,coronavirus disease 2019,sepsis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要